Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marcela Valderrama Maus, M.D., Ph.D.


Available: 04/05/22, Expires: 06/01/23

Our work focuses on CAR T cells and other kinds of immune cell engineering. Our goal is to develop new therapies for patients, and also find out how they work and how they fail in patients.

Characterization of Dexamethasone Suppression of Chimeric Antigen Receptor (CAR) T Cells Targeting Glioblastoma Multiforme
Full Time/Year Long, 09/01/17 - 06/30/18
Targeting Tumor Heterogeneity in the Treatment of Glioblastoma Multiforme (GBM) Using BiTE-Secreting EGFRvIII CAR T-cells
Soma Weiss, 09/01/17 - 03/30/19

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA249062 (MAUS, MARCELA VALDERRAMA) Jan 7, 2021 - Dec 31, 2025
    Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells
    Role: Principal Investigator
  2. R01CA252940 (MAUS, MARCELA VALDERRAMA) Sep 1, 2020 - May 31, 2025
    Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel
    Role: Principal Investigator
  3. R01CA238268 (MAUS, MARCELA VALDERRAMA) Sep 20, 2019 - Aug 31, 2024
    Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies
    Role: Principal Investigator
  4. K08CA166039 (MAUS, MARCELA VALDERRAMA) Sep 19, 2012 - Aug 31, 2017
    Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bailey SR, Berger TR, Graham C, Larson RC, Maus MV. Four challenges to CAR T cells breaking the glass ceiling. Eur J Immunol. 2022 Dec 31; e2250039. PMID: 36585889.
    Citations:    Fields:    
  2. Hagel KR, Arafeh R, Gang S, Arnoff TE, Larson RC, Doench JG, Mathewson ND, Wucherpfennig KW, Maus MV, Hahn WC. Systematic interrogation of tumor cell resistance to CAR T cell therapy in pancreatic cancer. Cancer Res. 2022 Dec 22. PMID: 36548402.
    Citations:    Fields:    
  3. Irvine DJ, Maus MV, Mooney DJ, Wong WW. The future of engineered immune cell therapies. Science. 2022 11 25; 378(6622):853-858. PMID: 36423279.
    Citations:    Fields:    Translation:HumansCells
  4. Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022 11 08; 6(21):5774-5785. PMID: 35349631; PMCID: PMC9647791.
    Citations: 4     Fields:    
  5. Graham CE, Maus MV. CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment. Blood Cancer Discov. 2022 11 02; 3(6):478-480. PMID: 36026510.
    Citations:    Fields:    Translation:HumansCells
  6. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov; 9(11):e833-e843. PMID: 36228643.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  7. Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022 09; 28(9):1848-1859. PMID: 36097221; PMCID: PMC9509487.
    Citations: 1     Fields:    Translation:HumansCells
  8. Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV. Nomenclature for Cellular and Genetic Therapies: A Need for Standardization. Transplant Cell Ther. 2022 12; 28(12):795-801. PMID: 36058548; PMCID: PMC9729423.
    Citations:    Fields:    
  9. Gaballa MR, Maus MV. High antigen density of BCMA: friend or foe to CAR T cells? J Immunother Cancer. 2022 09; 10(9). PMID: 36137650; PMCID: PMC9511652.
    Citations:    Fields:    Translation:HumansCells
  10. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Maus MV. Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals. Clin Infect Dis. 2022 08 24; 75(1):e869-e873. PMID: 35278306; PMCID: PMC9402689.
    Citations:    Fields:    
  11. Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med (N Y). 2022 08 12; 3(8):538-564. PMID: 35963235.
    Citations: 1     Translation:HumansCells
  12. Jing R, Scarfo I, Najia MA, Lummertz da Rocha E, Han A, Sanborn M, Bingham T, Kubaczka C, Jha DK, Falchetti M, Schlaeger TM, North TE, Maus MV, Daley GQ. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 2022 08 04; 29(8):1181-1196.e6. PMID: 35931029.
    Citations: 2     Fields:    Translation:HumansCells
  13. Maus MV. Safety of genetically modified T cells. Blood. 2022 07 07; 140(1):1-2. PMID: 35797018.
    Citations:    Fields:    Translation:HumansCells
  14. Villalba JA, Maus MV, Frigault MJ, Zaffini R, Gandhi RT, Rosenberg ES, Siedner MJ. False-Positive Human Immunodeficiency Virus Test Results in Patients Receiving Lentivirus-Based Chimeric Antigen Receptor T-Cell Therapy: Case Report, Review of the Literature, and Proposed Recommendations. J Infect Dis. 2022 06 01; 225(11):1933-1936. PMID: 34927686.
    Citations:    Fields:    Translation:HumansCells
  15. Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell E, Raje N, Cook D, Yee AJ, Logan E, Avigan D, Jakubowiak AJ, Shaw KL, Daley H, Nikiforow S, Griffin FM, Cornwell C, Shen A, Heery C, Maus MV. Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2022 Apr 25. PMID: 35468618.
    Citations:    Fields:    
  16. Leick MB, Silva H, Scarfò I, Larson R, Choi BD, Bouffard AA, Gallagher K, Schmidts A, Bailey SR, Kann MC, Jan M, Wehrli M, Grauwet K, Horick N, Frigault MJ, Maus MV. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022 05 09; 40(5):494-508.e5. PMID: 35452603; PMCID: PMC9107929.
    Citations: 1     Fields:    Translation:HumansCells
  17. Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022 04 14; 139(15):2306-2315. PMID: 35167655; PMCID: PMC9012129.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  18. Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. CAR T cell killing requires the IFN?R pathway in solid but not liquid tumours. Nature. 2022 04; 604(7906):563-570. PMID: 35418687.
    Citations: 2     Fields:    Translation:HumansCells
  19. Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, Zhang F. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun. 2022 03 25; 13(1):1606. PMID: 35338135; PMCID: PMC8956604.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  20. Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin M, Regan C, Blumenthal KG, Banerji A, Judd AD, Scorsune KJ, McGree BM, Sherburne MM, Lynch JM, Weitzman JI, Lei M, Kotton CN, Dighe AS, Maus MV, Alter G, Abramson JS, Soumerai JD. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022 03 22; 6(6):1671-1683. PMID: 35073571; PMCID: PMC8789382.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  21. Maus MV. A decade of CAR T cell evolution. Nat Cancer. 2022 03; 3(3):270-271. PMID: 35288717.
    Citations: 1     Translation:Cells
  22. Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KME, Frigault MJ, Maus MV. Blockade or Deletion of IFN? Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discov. 2022 03 01; 3(2):136-153. PMID: 35015685; PMCID: PMC9414118.
    Citations: 5     Fields:    Translation:HumansCells
  23. How J, Gallagher KME, Liu Y, Katsis K, Elder EL, Larson RC, Leick MB, Neuberg D, Maus MV, Hobbs GS. Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia. 2022 04; 36(4):1176-1179. PMID: 35217807; PMCID: PMC8873343.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  24. Petri K, Zhang W, Ma J, Schmidts A, Lee H, Horng JE, Kim DY, Kurt IC, Clement K, Hsu JY, Pinello L, Maus MV, Joung JK, Yeh JJ. Author Correction: CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. Nat Biotechnol. 2022 Feb; 40(2):273. PMID: 33986547.
    Citations:    Fields:    
  25. Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022 01; 10(1). PMID: 34996813; PMCID: PMC8744112.
    Citations: 4     Fields:    Translation:Humans
  26. Yan C, Yang Q, Zhang S, Millar DG, Alpert EJ, Do D, Veloso A, Brunson DC, Drapkin BJ, Stanzione M, Scarfò I, Moore JC, Iyer S, Qin Q, Wei Y, McCarthy KM, Rawls JF, Dyson NJ, Cobbold M, Maus MV, Langenau DM. Single-cell imaging of T cell immunotherapy responses in vivo. J Exp Med. 2021 10 04; 218(10). PMID: 34415995; PMCID: PMC8383813.
    Citations:    Fields:    Translation:HumansAnimalsCells
  27. Kong W, Dimitri A, Wang W, Jung IY, Ott CJ, Fasolino M, Wang Y, Kulikovskaya I, Gupta M, Yoder T, DeNizio JE, Everett JK, Williams EF, Xu J, Scholler J, Reich TJ, Bhoj VG, Haines KM, Maus MV, Melenhorst JJ, Young RM, Jadlowsky JK, Marcucci KT, Bradner JE, Levine BL, Porter DL, Bushman FD, Kohli RM, June CH, Davis MM, Lacey SF, Vahedi G, Fraietta JA. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J Clin Invest. 2021 08 16; 131(16). PMID: 34396987; PMCID: PMC8363276.
    Citations: 7     Fields:    Translation:HumansCells
  28. Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986. PMID: 34342642; PMCID: PMC8361461.
    Citations: 4     Fields:    Translation:Humans
  29. Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. PMID: 34377737; PMCID: PMC8322039.
    Citations: 2     
  30. Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Curr Opin Pharmacol. 2021 08; 59:116-126. PMID: 34198161.
    Citations:    Fields:    Translation:HumansCells
  31. Yu X, Curry WT, Gerstner ER, Cahill DP, Nahed BV, Maus MV, Carter BS, Choi BD. Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. Neurosurgery. 2021 06 15; 89(1):E68-E69. PMID: 33826726.
    Citations:    Fields:    Translation:Humans
  32. Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplant Cell Ther. 2021 10; 27(10):807-816. PMID: 34107340; PMCID: PMC8478786.
    Citations:    Fields:    Translation:Humans
  33. Maus MV. CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia. Lancet. 2021 08 07; 398(10299):466-467. PMID: 34097851.
    Citations: 2     Fields:    Translation:HumansCells
  34. Weingarten-Gabbay S, Klaeger S, Sarkizova S, Pearlman LR, Chen DY, Gallagher KME, Bauer MR, Taylor HB, Dunn WA, Tarr C, Sidney J, Rachimi S, Conway HL, Katsis K, Wang Y, Leistritz-Edwards D, Durkin MR, Tomkins-Tinch CH, Finkel Y, Nachshon A, Gentili M, Rivera KD, Carulli IP, Chea VA, Chandrashekar A, Bozkus CC, Carrington M, Bhardwaj N, Barouch DH, Sette A, Maus MV, Rice CM, Clauser KR, Keskin DB, Pregibon DC, Hacohen N, Carr SA, Abelin JG, Saeed M, Sabeti PC. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell. 2021 07 22; 184(15):3962-3980.e17. PMID: 34171305; PMCID: PMC8173604.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  35. Durgin JS, Henderson F, Nasrallah MP, Mohan S, Wang S, Lacey SF, Melenhorst JJ, Desai AS, Lee JYK, Maus MV, June CH, Brem S, O'Connor RS, Binder Z, O'Rourke DM. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. Front Oncol. 2021; 11:669071. PMID: 34026647.
    Citations: 4     
  36. Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, Brini G, Grauwet K, Maus MV. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv. 2021 May 03. PMID: 33972942; PMCID: PMC8109204.
    Citations: 1     
  37. Bai Z, Lundh S, Kim D, Woodhouse S, Barrett DM, Myers RM, Grupp SA, Maus MV, June CH, Camara PG, Melenhorst JJ, Fan R. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. J Immunother Cancer. 2021 05; 9(5). PMID: 34006631.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  38. Petri K, Zhang W, Ma J, Schmidts A, Lee H, Horng JE, Kim DY, Kurt IC, Clement K, Hsu JY, Pinello L, Maus MV, Joung JK, Yeh JJ. CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. Nat Biotechnol. 2022 02; 40(2):189-193. PMID: 33927418; PMCID: PMC8553808.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  39. Johansson U, Gallagher K, Burgoyne V, Maus MV, Casey KS, Brini GG, Frigault MJ, Yam JY, Chavda N, Besley C, Lugthart S. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories. Cytometry B Clin Cytom. 2021 11; 100(6):622-631. PMID: 33915021.
    Citations:    Fields:    Translation:Humans
  40. Berger TR, Maus MV. Mechanisms of response and resistance to CAR T cell therapies. Curr Opin Immunol. 2021 04; 69:56-64. PMID: 33752101.
    Citations: 6     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  41. Clayton KL, Mylvaganam G, Villasmil-Ocando A, Stuart H, Maus MV, Rashidian M, Ploegh HL, Walker BD. HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell Host Microbe. 2021 03 10; 29(3):435-447.e9. PMID: 33571449; PMCID: PMC8486985.
    Citations: 8     Fields:    Translation:HumansCells
  42. Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021 03; 21(3):145-161. PMID: 33483715; PMCID: PMC8353572.
    Citations: 82     Fields:    Translation:HumansAnimalsCells
  43. Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA, Gasser JA, Slabicki M, Bouffard AA, Castano AP, Kann MC, Cabral ML, Tepper A, Grinshpun DE, Sperling AS, Kyung T, Sievers QL, Birnbaum ME, Maus MV, Ebert BL. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021 01 06; 13(575). PMID: 33408186; PMCID: PMC8045771.
    Citations: 30     Fields:    Translation:HumansCells
  44. Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020 12 12; 396(10266):1885-1894. PMID: 33308471.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  45. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 12; 8(2). PMID: 33335028.
    Citations: 38     Fields:    Translation:Humans
  46. Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Adv. 2020 11 24; 4(22):5858-5862. PMID: 33232481.
    Citations: 3     Fields:    Translation:HumansCells
  47. Leick MB, Maus MV, Frigault MJ. Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Mol Ther. 2021 02 03; 29(2):433-441. PMID: 33130313; PMCID: PMC7854294.
    Citations: 9     Fields:    Translation:HumansCells
  48. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438. PMID: 32615600.
    Citations: 14     Fields:    Translation:Humans
  49. Schmidts A, Marsh LC, Srivastava AA, Bouffard AA, Boroughs AC, Scarfò I, Larson RC, Bedoya F, Choi BD, Frigault MJ, Bailey SR, Leick MB, Vatsa S, Kann MC, Prew MS, Kleinstiver BP, Joung JK, Maus MV. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. J Immunother Cancer. 2020 09; 8(2). PMID: 32900862.
    Citations: 5     Fields:    Translation:HumansCells
  50. Schmidts A, Wehrli M, Maus MV. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. Annu Rev Med. 2021 01 27; 72:365-382. PMID: 32776808.
    Citations: 4     Fields:    Translation:HumansCells
  51. Maus MV, Lionakis MS. Infections associated with the new 'nibs and mabs' and cellular therapies. Curr Opin Infect Dis. 2020 08; 33(4):281-289. PMID: 32657964; PMCID: PMC7367497.
    Citations: 2     Fields:    Translation:Humans
  52. Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, Lorrey SJ, Ashenberg O, Jerby L, Hofree M, Smith-Rosario G, Morris R, Gould J, Riley LS, Berger TR, Riesenfeld SJ, Rozenblatt-Rosen O, Choi BD, Regev A, Maus MV. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Mol Ther. 2020 12 02; 28(12):2577-2592. PMID: 32755564.
    Citations: 21     Fields:    Translation:HumansCells
  53. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 09 20; 38(27):3095-3106. PMID: 32667831; PMCID: PMC7499617.
    Citations: 49     Fields:    Translation:HumansCells
  54. Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Publisher Correction: Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2020 Jul; 38(7):901. PMID: 32541959.
    Citations: 2     Fields:    
  55. Maryamchik E, Gallagher KME, Preffer FI, Kadauke S, Maus MV. New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry. Cytometry B Clin Cytom. 2020 07; 98(4):299-327. PMID: 32352629.
    Citations: 4     Fields:    Translation:HumansCells
  56. Gutierrez C, Brown ART, Herr MM, Kadri SS, Hill B, Rajendram P, Duggal A, Turtle CJ, Patel K, Lin Y, May HP, Gallo de Moraes A, Maus MV, Frigault MJ, Brudno JN, Athale J, Shah NN, Kochenderfer JN, Dharshan A, Beitinjaneh A, Arias AS, McEvoy C, Mead E, Stephens RS, Nates JL, Neelapu SS, Pastores SM. The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. J Crit Care. 2020 08; 58:58-64. PMID: 32361219.
    Citations: 11     Fields:    Translation:Humans
  57. Weber EW, Maus MV, Mackall CL. The Emerging Landscape of Immune Cell Therapies. Cell. 2020 04 02; 181(1):46-62. PMID: 32243795; PMCID: PMC8900215.
    Citations: 64     Fields:    Translation:Humans
  58. Ascierto PA, Fox BA, Urba WJ, Anderson AC, Atkins MB, Borden EC, Brahmer JR, Butterfield LH, Cesano A, Chen DC, de Gruijl TD, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Stephen Hodi FJ, Hwu P, Kaufman D, Kaufman HL, Lotze MT, McNeel DG, Margolin KM, Marincola FM, Mastrangelo MJ, Maus MV, Parkinson DR, Romero PJ, Sondel PM, Spranger S, Sznol M, Weiner GJ, Wigginton JM, Weber JS. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020 04; 8(1). PMID: 32300051.
    Citations: 38     Fields:    Translation:HumansCellsPHPublic Health
  59. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020 04 01; 130(4):1586-1594. PMID: 32235098; PMCID: PMC7108913.
    Citations: 27     Fields:    Translation:HumansCells
  60. Scarfò I, Maus MV. Unraveling the Signaling Balance of Activation and Exhaustion of CAR T Cells. Cancer Cell. 2020 02 10; 37(2):143-144. PMID: 32049043.
    Citations: 2     Fields:    Translation:HumansCells
  61. Nardi V, Ku N, Frigault MJ, Dubuc AM, Tsai HK, Amrein PC, Hobbs GS, Brunner AM, Narayan R, Burke ME, Foster J, Dal Cin P, Maus MV, Fathi AT, Hock H. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111. PMID: 31905241.
    Citations: 8     Fields:    Translation:HumansCells
  62. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019 11 14; 7(1):304. PMID: 31727131.
    Citations: 75     Fields:    Translation:HumansAnimalsCells
  63. Maus MV, Leick MB, Cornejo KM, Nardi V. Case 35-2019: A 66-Year-Old Man with Pancytopenia and Rash. N Engl J Med. 2019 Nov 14; 381(20):1951-1960. PMID: 31722157.
    Citations: 1     Fields:    Translation:Humans
  64. Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260. PMID: 31698455.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  65. Mondal N, Silva M, Castano AP, Maus MV, Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. J Biol Chem. 2019 11 29; 294(48):18465-18474. PMID: 31628196.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  66. Resar LM, Jaffee EM, Armanios M, Jackson S, Azad NS, Horton MR, Kaplan MJ, Laiho M, Maus MV, Sumner CJ, Wheelan SJ, Wills-Karp M. Equity and diversity in academic medicine: a perspective from the JCI editors. J Clin Invest. 2019 10 01; 129(10):3974-3977. PMID: 31524636; PMCID: PMC6763240.
    Citations: 3     Fields:    Translation:Humans
  67. Wang X, Scarfò I, Schmidts A, Toner M, Maus MV, Irimia D. Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays. Adv Sci (Weinh). 2019 Dec; 6(23):1901829. PMID: 31832320; PMCID: PMC6891905.
    Citations: 6     Fields:    
  68. Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol. 2019; 10:2109. PMID: 31552045.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  69. Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis. 2019 08 30; 69(6):909-920. PMID: 30520987.
    Citations: 22     Fields:    Translation:Humans
  70. Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Christensen JH, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res. 2019 12 01; 25(23):7046-7057. PMID: 31439577; PMCID: PMC6891163.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  71. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019 09; 37(9):1049-1058. PMID: 31332324.
    Citations: 141     Fields:    Translation:HumansAnimalsCells
  72. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019 09 12; 134(11):860-866. PMID: 31320380; PMCID: PMC7022436.
    Citations: 57     Fields:    Translation:HumansCells
  73. Li M, Chin LY, Shukor S, Tamayo AG, Maus MV, Parekkadan B. Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression. Autoimmunity. 2019 05; 52(3):102-107. PMID: 31238751.
    Citations:    Fields:    Translation:HumansCells
  74. Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019 12; 37(12):1425-1434. PMID: 31160723.
    Citations: 53     Fields:    Translation:HumansCells
  75. Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, Le B, Morath A, Baldeviano GC, Quinn J, Tavares P, Wei Q, Weiler S, Maus MV, Getts D, Schamel WW, Hofmeister R. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. 2019 05 07; 10(1):2087. PMID: 31064990.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  76. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737. PMID: 31042825; PMCID: PMC8202968.
    Citations: 416     Fields:    Translation:HumansCellsCTClinical Trials
  77. Scarfò I, Frigault MJ, Maus MV. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. Front Oncol. 2019; 9:259. PMID: 31058076; PMCID: PMC6477509.
    Citations: 4     
  78. Leick M, Maus MV. Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer. Cancer Discov. 2019 Apr; 9(4):466-468. PMID: 30936218.
    Citations: 4     Fields:    Translation:Humans
  79. Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function. JCI Insight. 2019 03 14; 5. PMID: 30869654.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  80. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations: 67     Fields:    Translation:Humans
  81. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2019 02 21; 4(4). PMID: 30830874.
    Citations: 16     Fields:    
  82. Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat Biotechnol. 2019 03; 37(3):276-282. PMID: 30742127; PMCID: PMC6401248.
    Citations: 141     Fields:    Translation:HumansCells
  83. Leick MB, Maus MV. CAR-T cells beyond CD19, UnCAR-Ted territory. Am J Hematol. 2019 05; 94(S1):S34-S41. PMID: 30632631.
    Citations: 1     Fields:    Translation:Humans
  84. Guedan S, Calderon H, Posey AD, Maus MV. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019 Mar 15; 12:145-156. PMID: 30666307; PMCID: PMC6330382.
    Citations: 113     
  85. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 04; 25(4):625-638. PMID: 30592986.
    Citations: 485     Fields:    Translation:Humans
  86. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137. PMID: 30514386.
    Citations: 75     Fields:    Translation:HumansAnimalsCells
  87. Li M, Chin LY, Shukor S, Tamayo A, Maus MV, Parekkadan B. Closed loop bioreactor system for the ex vivo expansion of human T cells. Cytotherapy. 2019 01; 21(1):76-82. PMID: 30497956; PMCID: PMC6333522.
    Citations: 1     Fields:    Translation:HumansCells
  88. Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Clin Cancer Res. 2019 04 01; 25(7):2042-2048. PMID: 30446589.
    Citations: 36     Fields:    Translation:HumansAnimalsCells
  89. Schmidts A, Maus MV. Making CAR T Cells a Solid Option for Solid Tumors. Front Immunol. 2018; 9:2593. PMID: 30467505.
    Citations: 69     Fields:    Translation:HumansAnimalsCells
  90. Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018 10 04; 132(14):1495-1506. PMID: 30089630; PMCID: PMC6172564.
    Citations: 50     Fields:    Translation:HumansAnimalsCells
  91. Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine DJ. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018 09; 36(8):707-716. PMID: 29985479; PMCID: PMC6078803.
    Citations: 124     Fields:    Translation:HumansAnimalsCells
  92. Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, Olabisi RM, Libutti S, Tischfield J, Maus MV, Deans R, Barcia RN, Anderson DG, Ritz J, Preti R, Parekkadan B. Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018 06; 2(6):362-376. PMID: 31011198; PMCID: PMC6594100.
    Citations: 41     Fields:    Translation:Humans
  93. Maus MV. Tumour tamed by transfer of one T cell. Nature. 2018 06; 558(7709):193-195. PMID: 29895908.
    Citations:    Fields:    Translation:HumansCells
  94. Choi BD, Curry WT, Carter BS, Maus MV. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons. Neurosurg Focus. 2018 06; 44(6):E13. PMID: 29852773.
    Citations: 10     Fields:    Translation:HumansCells
  95. Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-ß Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018 07 05; 26(7):1855-1866. PMID: 29807781.
    Citations: 171     Fields:    Translation:HumansCellsCTClinical Trials
  96. Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018 04 19; 3(8). PMID: 29669947.
    Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
  97. Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018 06; 31(2):158-165. PMID: 29909916.
    Citations: 3     Fields:    Translation:Humans
  98. Choi BD, O'Rourke DM, Maus MV. Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma. J Target Ther Cancer. 2017 Aug; 6(4):22-25. PMID: 29167820; PMCID: PMC5695679.
    Citations: 10     
  99. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 07 19; 9(399). PMID: 28724573; PMCID: PMC5762203.
    Citations: 528     Fields:    Translation:HumansCTClinical Trials
  100. Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064. PMID: 28714866; PMCID: PMC5531425.
    Citations: 131     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  101. Sampson JH, Maus MV, June CH. Immunotherapy for Brain Tumors. J Clin Oncol. 2017 Jul 20; 35(21):2450-2456. PMID: 28640704.
    Citations: 52     Fields:    Translation:Humans
  102. Maus MV, Nikiforow S. The Why, what, and How of the New FACT standards for immune effector cells. J Immunother Cancer. 2017; 5:36. PMID: 28428885.
    Citations: 12     Fields:    Translation:Humans
  103. Ormhøj M, Bedoya F, Frigault MJ, Maus MV. CARs in the Lead Against Multiple Myeloma. Curr Hematol Malig Rep. 2017 04; 12(2):119-125. PMID: 28233151.
    Citations: 14     Fields:    Translation:HumansCells
  104. Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells. J Immunother. 2017 04; 40(3):104-107. PMID: 28234665.
    Citations: 24     Fields:    Translation:HumansCells
  105. Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017; 5:28. PMID: 28331617.
    Citations: 84     Fields:    Translation:HumansAnimalsCells
  106. Maus MV. Immunology: T-cell tweaks to target tumours. Nature. 2017 03 02; 543(7643):48-49. PMID: 28225762.
    Citations: 3     Fields:    Translation:HumansCells
  107. Bedoya F, Frigault MJ, Maus MV. The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Mol Ther. 2017 02 01; 25(2):314-320. PMID: 28153085; PMCID: PMC5368422.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  108. Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics. 2016; 3:1-9. PMID: 29675462; PMCID: PMC5904357.
    Citations: 33     
  109. Ruella M, Maus MV. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016; 14:357-362. PMID: 27761200.
    Citations: 106     
  110. Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res. 2016 Apr 15; 22(8):1875-84. PMID: 27084741; PMCID: PMC4843171.
    Citations: 110     Fields:    Translation:HumansAnimals
  111. Fesnak A, Lin C, Siegel DL, Maus MV. CAR-T Cell Therapies From the Transfusion Medicine Perspective. Transfus Med Rev. 2016 07; 30(3):139-45. PMID: 27067907.
    Citations: 18     Fields:    Translation:HumansCells
  112. Frigault MJ, Maus MV. Chimeric antigen receptor-modified T cells strike back. Int Immunol. 2016 07; 28(7):355-63. PMID: 27021308; PMCID: PMC4922025.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  113. Maus MV, Levine BL. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Oncologist. 2016 05; 21(5):608-17. PMID: 27009942; PMCID: PMC4861363.
    Citations: 36     Fields:    Translation:HumansCells
  114. Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol. 2016 06; 40:24-35. PMID: 26963133; PMCID: PMC4884546.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  115. Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol. 2016 Apr; 43(2):291-9. PMID: 27040708; PMCID: PMC4824551.
    Citations: 8     Fields:    Translation:HumansCells
  116. Maus MV. Innate immune signaling in CLL. Blood. 2016 Jan 28; 127(4):376-8. PMID: 26823508.
    Citations:    Fields:    Translation:Humans
  117. Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clin Cancer Res. 2016 06 01; 22(11):2684-96. PMID: 26819453.
    Citations: 77     Fields:    Translation:HumansAnimalsCells
  118. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar 03; 127(9):1117-27. PMID: 26813675; PMCID: PMC4778162.
    Citations: 186     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  119. Miller BC, Maus MV. CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies. Oncol Res Treat. 2015; 38(12):683-90. PMID: 26633875.
    Citations: 6     Fields:    Translation:HumansCells
  120. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016 05; 30(3):157-67. PMID: 26574053.
    Citations: 84     Fields:    Translation:HumansAnimalsCells
  121. Maus MV, Powell DJ. Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity. Cancer J. 2015 Nov-Dec; 21(6):475-9. PMID: 26588679.
    Citations: 5     Fields:    Translation:Humans
  122. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015 Sep 10; 373(11):1040-7. PMID: 26352815; PMCID: PMC4646711.
    Citations: 249     Fields:    Translation:HumansCTClinical Trials
  123. Maus MV. Designing CAR T cells for glioblastoma. Oncoimmunology. 2015 Dec; 4(12):e1048956. PMID: 26587317.
    Citations: 13     Fields:    
  124. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22. PMID: 25696001; PMCID: PMC4467166.
    Citations: 204     Fields:    Translation:HumansAnimals
  125. June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, Grupp SA, Porter DL. Engineered T cells for cancer therapy. Cancer Immunol Immunother. 2014 Sep; 63(9):969-75. PMID: 24943274.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  126. Maus MV, June CH. CARTs on the road for myeloma. Clin Cancer Res. 2014 Aug 01; 20(15):3899-901. PMID: 24919574.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  127. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 24; 123(17):2625-35. PMID: 24578504; PMCID: PMC3999751.
    Citations: 279     Fields:    Translation:HumansCells
  128. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 Feb; 2(2):112-20. PMID: 24579088; PMCID: PMC3932715.
    Citations: 357     Fields:    Translation:HumansCellsCTClinical Trials
  129. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014; 32:189-225. PMID: 24423116.
    Citations: 136     Fields:    Translation:HumansAnimalsCells
  130. Garfall AL, Fraietta JA, Maus MV. Immunotherapy with chimeric antigen receptors for multiple myeloma. Discov Med. 2014 Jan; 17(91):37-46. PMID: 24411699.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  131. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul; 1:26-31. PMID: 24432303.
    Citations: 93     Fields:    
  132. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013 Aug 08; 122(6):863-71. PMID: 23770775; PMCID: PMC3743463.
    Citations: 472     Fields:    Translation:HumansCells
  133. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013 Jul; 1(1):26-31. PMID: 24777247.
    Citations: 152     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  134. Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):1917-9. PMID: 23444214.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  135. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, Zhou S, Murphy SL, Maus MV, Mingozzi F, Orange JS, High KA. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest. 2009 Jun; 119(6):1688-95. PMID: 19436115; PMCID: PMC2689109.
    Citations: 85     Fields:    Translation:HumansCells
  136. Maus MV, Posencheg MA, Geddes K, Elkan M, Peñaranda S, Oberste MS, Hodinka RL. Detection of echovirus 18 in human breast milk. J Clin Microbiol. 2008 Mar; 46(3):1137-40. PMID: 18199781; PMCID: PMC2268343.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  137. Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol. 2007 Oct 01; 179(7):4910-8. PMID: 17878391; PMCID: PMC3809056.
    Citations: 100     Fields:    Translation:HumansCells
  138. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007 Apr; 13(4):419-22. PMID: 17369837.
    Citations: 316     Fields:    Translation:HumansAnimalsCells
  139. Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH. Extensive replicative capacity of human central memory T cells. J Immunol. 2004 Jun 01; 172(11):6675-83. PMID: 15153483.
    Citations: 14     Fields:    Translation:HumansCells
  140. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med. 2003 May; 9(5):619-24. PMID: 12704385.
    Citations: 112     Fields:    Translation:HumansCells
  141. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res. 2003 Apr; 9(4):1517-27. PMID: 12684428.
    Citations: 36     Fields:    Translation:HumansCells
  142. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol. 2003 Jan; 106(1):16-22. PMID: 12584046.
    Citations: 19     Fields:    Translation:HumansCells
  143. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol. 2002 Dec; 105(3):259-72. PMID: 12498807.
    Citations: 30     Fields:    Translation:HumansCells
  144. Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):15006-11. PMID: 12419850; PMCID: PMC137535.
    Citations: 13     Fields:    Translation:HumansCells
  145. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002 Feb; 20(2):143-8. PMID: 11821859.
    Citations: 144     Fields:    Translation:HumansCells
  146. Cosar CB, Cohen EJ, Rapuano CJ, Maus M, Penne RP, Flanagan JC, Laibson PR. Tarsorrhaphy: clinical experience from a cornea practice. Cornea. 2001 Nov; 20(8):787-91. PMID: 11685052.
    Citations: 18     Fields:    Translation:Humans
  147. Bernardino CR, Davidson RS, Maus M, Spaeth GL. Angle-closure glaucoma in association with orbital pseudotumor. Ophthalmology. 2001 Sep; 108(9):1603-6. PMID: 11535457.
    Citations: 3     Fields:    Translation:Humans
  148. Shanno G, Maus M, Bilyk J, Schwartz S, Savino P, Simeone F, Goldman HW. Image-guided transorbital roof craniotomy via a suprabrow approach: a surgical series of 72 patients. Neurosurgery. 2001 Mar; 48(3):559-67; discussion 567-8. PMID: 11270546.
    Citations: 7     Fields:    Translation:Humans
  149. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology. 1999 Nov; 140(11):5447-50. PMID: 10537179.
    Citations: 46     Fields:    Translation:HumansCells
  150. Rubin PA, Fay AM, Remulla HD, Maus M. Ophthalmic plastic applications of acellular dermal allografts. Ophthalmology. 1999 Nov; 106(11):2091-7. PMID: 10571342.
    Citations: 8     Fields:    Translation:Humans
  151. Maus M, Goldman HW. Removal of orbital apex hemangioma using new transorbital craniotomy through suprabrow approach. Ophthalmic Plast Reconstr Surg. 1999 May; 15(3):166-70. PMID: 10355834.
    Citations: 3     Fields:    Translation:Humans
  152. Aldave AJ, Maus M, Rubin PA. Advances in the management of lower eyelid retraction. Facial Plast Surg. 1999; 15(3):213-24. PMID: 11816084.
    Citations: 1     Fields:    Translation:Humans
  153. Zobian J, Maus M. Thyroid-related ophthalmology. Curr Opin Ophthalmol. 1998 Dec; 9(6):105-10. PMID: 10387329.
    Citations:    Fields:    Translation:Humans
  154. Dei Cas R, Maus M, Bilyk J, Chang W, Eagle RC, Rubin P. Gore-Tex as an orbital implant material. Ophthalmic Plast Reconstr Surg. 1998 Nov; 14(6):425-31. PMID: 9842562.
    Citations:    Fields:    Translation:AnimalsCells
  155. Rubin PA, Popham J, Rumelt S, Remulla H, Bilyk JR, Holds J, Mannor G, Maus M, Patrinely JR. Enhancement of the cosmetic and functional outcome of enucleation with the conical orbital implant. Ophthalmology. 1998 May; 105(5):919-25. PMID: 9593398.
    Citations: 2     Fields:    Translation:Humans
  156. Neuenschwander MC, Pribitkin E, Lacombe V, Maus M, Rao V, Roth M. Frontoethmoid mucocele complicating Graves' ophthalmopathy. Ann Otol Rhinol Laryngol. 1998 May; 107(5 Pt 1):433-5. PMID: 9596224.
    Citations: 1     Fields:    Translation:Humans
  157. Kadam S, Maus M, Poddig J, Schmidt S, Rasmussen R, Novosad E, Plattner J, McAlpine J. Reversal of multidrug resistance by two novel indole derivatives. Cancer Res. 1992 Sep 01; 52(17):4735-40. PMID: 1355008.
    Citations: 2     Fields:    Translation:AnimalsCells
  158. Taylor A, Brown DP, Kadam S, Maus M, Kohlbrenner WE, Weigl D, Turon MC, Katz L. High-level expression and purification of mature HIV-1 protease in Escherichia coli under control of the araBAD promoter. Appl Microbiol Biotechnol. 1992 May; 37(2):205-10. PMID: 1368241.
    Citations: 4     Fields:    Translation:Cells
  159. Maus M, Katz LJ. Choroidal detachment, flat anterior chamber, and hypotony as complications of neodymium: YAG laser cyclophotocoagulation. Ophthalmology. 1990 Jan; 97(1):69-72. PMID: 2179798.
    Citations: 13     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Maus's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (457)
Co-Authors (131)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.